JPH07504222A - 化学的に規定されるオリゴ糖，該オリゴ糖の誘導体，擬態物及び該オリゴ糖に対する抗体による細胞接着の抑制 - Google Patents

化学的に規定されるオリゴ糖，該オリゴ糖の誘導体，擬態物及び該オリゴ糖に対する抗体による細胞接着の抑制

Info

Publication number
JPH07504222A
JPH07504222A JP5514925A JP51492593A JPH07504222A JP H07504222 A JPH07504222 A JP H07504222A JP 5514925 A JP5514925 A JP 5514925A JP 51492593 A JP51492593 A JP 51492593A JP H07504222 A JPH07504222 A JP H07504222A
Authority
JP
Japan
Prior art keywords
cells
carbohydrate
elam
antibody
adhesion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP5514925A
Other languages
English (en)
Japanese (ja)
Inventor
コジマ，ナオヤ
ハンダ，カズコ
ハコモリ，セン−イチロー
Original Assignee
ザ・バイオメンブレイン・インスティテュート
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ・バイオメンブレイン・インスティテュート filed Critical ザ・バイオメンブレイン・インスティテュート
Publication of JPH07504222A publication Critical patent/JPH07504222A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • C07K14/70564—Selectins, e.g. CD62
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C07K16/2854—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP5514925A 1992-02-19 1993-02-19 化学的に規定されるオリゴ糖，該オリゴ糖の誘導体，擬態物及び該オリゴ糖に対する抗体による細胞接着の抑制 Pending JPH07504222A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US83697892A 1992-02-19 1992-02-19
US836,978 1992-02-19
US95072092A 1992-09-25 1992-09-25
US950,720 1992-09-25
US99690392A 1992-12-29 1992-12-29
US996,903 1992-12-29
PCT/US1993/001375 WO1993017033A1 (fr) 1992-02-19 1993-02-19 Inhibition de l'adherence cellulaire par oligosaccharides definis chimiquement, leurs derives, des imitateurs et des anticorps

Publications (1)

Publication Number Publication Date
JPH07504222A true JPH07504222A (ja) 1995-05-11

Family

ID=27420263

Family Applications (1)

Application Number Title Priority Date Filing Date
JP5514925A Pending JPH07504222A (ja) 1992-02-19 1993-02-19 化学的に規定されるオリゴ糖，該オリゴ糖の誘導体，擬態物及び該オリゴ糖に対する抗体による細胞接着の抑制

Country Status (4)

Country Link
EP (1) EP0638085A1 (fr)
JP (1) JPH07504222A (fr)
CA (1) CA2129987A1 (fr)
WO (1) WO1993017033A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007297521A (ja) * 2006-04-28 2007-11-15 Noguchi Inst 多様性を表現するオリゴ糖またはその誘導体
JP2012100642A (ja) * 2010-11-11 2012-05-31 Tokyo Women's Medical College 細胞培養基材の評価方法

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2227013A1 (fr) 1995-07-14 1997-02-06 Glycotech Corp. Composes et methodes de traitement de cancers lies au recepteur egf et purification du recepteur egf
AUPP913999A0 (en) * 1999-03-12 1999-04-01 Biota Scientific Management Pty Ltd Novel chemical compounds and their use
DE19930177B4 (de) 1999-06-30 2007-02-08 Nikolai Vladimirovich Bovin Intermolekular assoziierende Verbindungen und deren Verwendung
DE10056136A1 (de) * 2000-11-07 2002-05-16 Nemod New Modalities Verwendung von Schwangerschaftsproteinen, Liposomen, nativen Muzin-Fragmenten und Mimikry-Verbindungen zur Behandlung und Prophylaxe von entzündlichen Erkrankungen, zur Verhinderung der Metastasierung und zur Prophylaxe von Tumorerkrankungen
US7374906B2 (en) 2000-11-08 2008-05-20 Surface Logix, Inc. Biological assays using gradients formed in microfluidic systems
US7326563B2 (en) 2000-11-08 2008-02-05 Surface Logix, Inc. Device and method for monitoring leukocyte migration
FI20011664A (fi) 2001-08-17 2003-02-18 Carbion Oy Syöpäpesifiset oligoskkaridisekvenssit ja niiden käyttö

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007297521A (ja) * 2006-04-28 2007-11-15 Noguchi Inst 多様性を表現するオリゴ糖またはその誘導体
JP2012100642A (ja) * 2010-11-11 2012-05-31 Tokyo Women's Medical College 細胞培養基材の評価方法

Also Published As

Publication number Publication date
EP0638085A1 (fr) 1995-02-15
CA2129987A1 (fr) 1993-09-02
WO1993017033A1 (fr) 1993-09-02

Similar Documents

Publication Publication Date Title
US6121233A (en) Methods for the inhibition of cancer metastasis mediated by endothelial adhesion molecules
Konstantopoulos et al. Cancer cells in transit: the vascular interactions of tumor cells
JP3201523B2 (ja) ヒト受容体における抗体−仲介異種移植拒絶を弱めるための方法および組成物
Satoh et al. Enhanced GM3 expression, associated with decreased invasiveness, is induced by brefeldin A in bladder cancer cells
Rittenhouse-Diakun et al. Development and characterization of monoclonal antibody to T-Antigen:(Galβl—3GalNAc-α-O)
Lloyd et al. Cell surface accessibility of individual gangliosides in malignant melanoma cells to antibodies is influenced by the total ganglioside composition of the cells
JPH06507927A (ja) 内皮結合のための化合物及び方法
EP0972782B1 (fr) Anticorps monoclonal reconnaissant l'oligosaccharide acide sialique n-glycolyle-galactose-glucose dans les tumeurs malignes et sa composition
Kannagi et al. Recent studies of glycolipid and glycoprotein profiles and characterization of the major glycolipid antigen in gastric cancer of a patient of blood group genotype pp (Tja-) first studied in 1951
JPH07504222A (ja) 化学的に規定されるオリゴ糖，該オリゴ糖の誘導体，擬態物及び該オリゴ糖に対する抗体による細胞接着の抑制
Leviatan Ben-Arye et al. Differential recognition of diet-derived Neu5Gc-neoantigens on glycan microarrays by carbohydrate-specific pooled human IgG and IgA antibodies
JP3066741B2 (ja) 癌細胞の増殖及び複製を抑制するための組成物
Spitalnik et al. Anti-My-28, an antigranulocyte mouse monoclonal antibody, binds to a sugar sequence in lacto-N-neotetraose
Watarai et al. Production of monoclonal antibodies directed to Hanganutziu-Deicher active gangliosides, N-glycolylneuraminic acid-containing gangliosides
JP2014141517A (ja) ポリシアル酸脱ｎ−アセチラーゼの阻害剤及びその使用方法
Gustafsson et al. A new generation of carbohydrate-based therapeutics: recombinant mucin-type fusion proteins as versatile inhibitors of protein–carbohydrate interactions
AU659808B2 (en) Inhibition of metastasis potential and invasiveness by oligosaccharides or oligosaccharide antigens or antibodies
JP2005535723A (ja) 腫瘍特異的オリゴ糖エピトープおよびその用途
JP2010156699A (ja) ヤドリギレクチンに対する個体の応答性を判定する方法
EP0521692A2 (fr) Inhibition de la potentiel métastasique et l'énvahissement par oligosaccharides ou ses conjugés
US5418129A (en) Blood treatment method
Carlsen et al. Isoglobotetraosylceramide is a marker for highly metastatic cells in rat mammary adenocarcinomas
JPH09216902A (ja) 動的流動系においてｅ−セレクチンに依存する細胞回転および付着を惹起する新規な炭水化物リガンド類（ミエロローリン）
Jegatheeswaran Mapping the Epitopes Recognized by Monoclonal Anti-Lewis X and Anti-Lewis A Antibodies
Gao Novel O-glycan arrays to characterize human cancer-associated epithelial antigens